enGene Therapeutics (ENGN) Long-Term Investments (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Long-Term Investments of $26.7 million for Q2 2026, down 21.7% year-over-year from $34.1 million in Q2 2025, and down 27.03% quarter-over-quarter from $36.6 million in Q1 2026.
enGene Therapeutics (ENGN) Long-Term Investments (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Long-Term Investments for 3 consecutive years, with $26.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Long-Term Investments fell 21.7% year-over-year to $26.7 million; the TTM figure through Apr 2026 stood at $26.7 million (down 21.7% YoY), while the FY2025 annual figure was $8.5 million, down 85.68% from the prior year.
- Long-Term Investments eased to $26.7 million in Q2 2026 per ENGN's latest filing, from $36.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $59.5 million in Q4 2024 and bottomed at $8.5 million in Q4 2025.
- Historically, Long-Term Investments has averaged $35.4 million across 3 years, with a median of $34.1 million in 2025.
- Annual changes were most pronounced in 2025 — Long-Term Investments sank 85.68% — and 2026, when it fell 21.7%.
- enGene Therapeutics' Long-Term Investments stood at $59.5 million in 2024, then tumbled by 85.68% to $8.5 million in 2025, then soared by 213.41% to $26.7 million in 2026.
- Business Quant data shows ENGN's Long-Term Investments at $26.7 million in Q2 2026, $36.6 million in Q1 2026, and $8.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 26.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 26.71 Mn |
| Jan 31, 2026 | 36.60 Mn |
| Oct 31, 2025 | 8.52 Mn |
| Jul 31, 2025 | 23.01 Mn |
| Apr 30, 2025 | 34.11 Mn |
| Jan 31, 2025 | 58.98 Mn |
| Oct 31, 2024 | 59.53 Mn |